Seaside Therapeutics Discontinues Arbaclofen (STX209) Extension Study

Published May 31, 2013 in The Boston Globe

Seaside Therapeutics has discontinued their extension study of Arbaclofen (STX209), a drug that showed promise in treating social impairment related to Fragile X syndrome.